Can the FDA regulate drug prices?

Are law-breaking pharma executives the new mob bosses? And can genome editing prevent heart attacks?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT's Ed Silverman joins us to discuss how the recent convictions of executives at Insys Therapeutics could shape the way drug companies are held accountable for misdeeds. Then, we break down a curious drug approval that will break up a rare disease monopoly. Finally, STAT's Sharon Begley stops by to explain an audacious startup's plan to take CRISPR from niche uses to the medical mainstream.

You can listen to the episode here. To listen to future episodes, be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.